CYP3A5 and POR Gene Polymorphisms As Predictors of Infection and Graft Rejection in Post-liver Transplant Patients Treated with Tacrolimus - a Cohort Study

Overview

Journal Pharmacogenomics J

Specialties Genetics
Molecular Biology
Pharmacology

Date 2025 Feb 24

PMID 39994182

Authors

Graziella D Agostino Ribeiro Naldi

Ariane Boccoli Minari

Thales D M Pereira

Victor Fossaluza

Nicholas Wagner Eugenio

Marcelo Alves Ferreira

Guilherme H Gregorio

Lucas Nacif

Luiz Augusto Carneiro D Albuquerque

Ricardo di Lazzaro Filho

Eduardo Luiz Rachid Cancado

Suzane Kioko Ono

Affiliations

Soon will be listed here.

Abstract

Liver transplantation is the only curative option for patients with advanced stages of liver disease, with tacrolimus used as the immunosuppressive drug of choice. Genetic variability can interfere with drug response, potentially leading to overexposure or underexposure. This study aims to investigate the association of CYP3A4 (rs2740574, rs2242480, rs35599367), CYP3A5 (rs776746, rs10264272), POR (rs1057868) and ABCB1 (rs1128503, rs2229109, rs9282564) gene polymorphisms with infection, acute rejection, and renal failure. The logistic regression model found an influence of CYP3A5 (rs776746) and POR28 (rs1057868) on the development of acute rejection after liver transplantation (p = 0.028). It also found an association between carriers of the variant allele of the POR*28 gene and infection.

References

Adam R, Karam V, Cailliez V, O Grady J, Mirza D, Cherqui D . 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. Transpl Int. 2018; 31(12):1293-1317. DOI: 10.1111/tri.13358. View

Bentata Y . Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2019; 44(2):140-152. DOI: 10.1111/aor.13551. View

Di Maira T, Little E, Berenguer M . Immunosuppression in liver transplant. Best Pract Res Clin Gastroenterol. 2020; 46-47:101681. DOI: 10.1016/j.bpg.2020.101681. View

Jeng L, Lee S, Soin A, Lee W, Suh K, Joo D . Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant. 2017; 18(6):1435-1446. DOI: 10.1111/ajt.14623. View

Weber M, Ibrahim H, Lake J . Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl. 2012; 18(11):1290-301. DOI: 10.1002/lt.23522. View

Noble J, Terrec F, Malvezzi P, Rostaing L . Adverse effects of immunosuppression after liver transplantation. Best Pract Res Clin Gastroenterol. 2021; 54-55:101762. DOI: 10.1016/j.bpg.2021.101762. View

Rubin A, Sanchez-Montes C, Aguilera V, San Juan F, Ferrer I, Moya A . Long-term outcome of 'long-term liver transplant survivors'. Transpl Int. 2013; 26(7):740-50. DOI: 10.1111/tri.12118. View

Brunet M, Pastor-Anglada M . Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics. Pharmaceutics. 2022; 14(9). PMC: 9503558. DOI: 10.3390/pharmaceutics14091755. View

Salvadori M, Tsalouchos A . Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapy. World J Transplant. 2020; 10(5):90-103. PMC: 7428791. DOI: 10.5500/wjt.v10.i5.90. View

10.

Turolo S, Edefonti A, Syren M, Montini G . Pharmacogenomics of Old and New Immunosuppressive Drugs for Precision Medicine in Kidney Transplantation. J Clin Med. 2023; 12(13). PMC: 10342352. DOI: 10.3390/jcm12134454. View

11.

Rodriguez-Antona C, Savieo J, Lauschke V, Sangkuhl K, Drogemoller B, Wang D . PharmVar GeneFocus: CYP3A5. Clin Pharmacol Ther. 2022; 112(6):1159-1171. PMC: 9399309. DOI: 10.1002/cpt.2563. View

12.

Schutte-Nutgen K, Tholking G, Suwelack B, Reuter S . Tacrolimus - Pharmacokinetic Considerations for Clinicians. Curr Drug Metab. 2018; 19(4):342-350. DOI: 10.2174/1389200219666180101104159. View

13.

Staatz C, Goodman L, Tett S . Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet. 2010; 49(3):141-75. DOI: 10.2165/11317350-000000000-00000. View

14.

Birdwell K, Decker B, Barbarino J, Peterson J, Stein C, Sadee W . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015; 98(1):19-24. PMC: 4481158. DOI: 10.1002/cpt.113. View

15.

Hendijani F, Azarpira N, Kaviani M . Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: A systematic review and meta-analysis. Clin Transplant. 2018; 32(8):e13306. DOI: 10.1111/ctr.13306. View

16.

Uesugi M, Kikuchi M, Shinke H, Omura T, Yonezawa A, Matsubara K . Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. Pharmacogenet Genomics. 2014; 24(7):356-66. DOI: 10.1097/FPC.0000000000000060. View

17.

Shah R . Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci. 2005; 360(1460):1617-38. PMC: 1569525. DOI: 10.1098/rstb.2005.1693. View

18.

Neuberger J, Bechstein W, Kuypers D, Burra P, Citterio F, de Geest S . Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation. 2017; 101(4S Suppl 2):S1-S56. DOI: 10.1097/TP.0000000000001651. View

19.

Kelava T, Turcic P, Markotic A, Ostojic A, Sisl D, Mrzljak A . Importance of genetic polymorphisms in liver transplantation outcomes. World J Gastroenterol. 2020; 26(12):1273-1285. PMC: 7109269. DOI: 10.3748/wjg.v26.i12.1273. View

20.

Lee D, Lee H, Yoon H, Yee J, Gwak H . Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis. Pharmaceutics. 2022; 14(2). PMC: 8877595. DOI: 10.3390/pharmaceutics14020261. View